Fight Continues Against Trump Administration Changes To 340B Drug Discount Program

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The American Hospital Association, four safety-net hospitals and the Maine Hospital Association have sued the Trump administration over a planned change to the 340B drug discount program. The change would require hospitals to pay full drug prices upfront and seek rebates after dispensing medicines; the groups say it could add more than $1 billion in annual administrative costs. A court decision is expected before the policy is scheduled to begin in January 2027.

The American Hospital Association (AHA), four safety-net hospitals and the Maine Hospital Association have sued the Trump administration to stop a planned change to the federal 340B drug discount program, arguing the new rebate system could raise costs and administrative demands before it takes effect in January 2027. The case asks a federal court to cancel the change and restore the current arrangement, under which eligible hospitals receive discounts before dispensing drugs.

Under the proposed system, hospitals would initially pay the regular price for covered medicines. After dispensing a drug, they would submit a claim to receive a rebate. The current system instead gives participating hospitals an upfront discount, described in the source report as about 13% for generic drugs and 23% for brand-name drugs. The lawsuit seeks to block the change and return to the status quo.

The AHA says estimates indicate the rebate mechanism could create more than $1 billion in annual administrative costs for hospitals. The association argues that paying more upfront and managing rebate claims would divert resources from care. The 340B program is administered by the Health Resources and Services Administration (HRSA) and provides discounted medicines to qualifying organizations serving low-income and other vulnerable patients.

HRSA figures cited in the report show covered entities spent $100 billion on 340B drugs in 2025, up from $81.4 billion in 2024 and $66.3 billion in 2023. Those figures describe spending on 340B drugs; they do not by themselves establish how much hospitals saved or how the savings were used. Drug manufacturers, represented by the Pharmaceutical Research and Manufacturers of America (PhRMA), argue that the program has grown too large and lacks adequate oversight of hospitals’ use of savings.

How Rebates Could Affect Hospital Budgets

The dispute centers on when hospitals receive the discount, not whether the program offers one. Requiring hospitals to pay full prices first could increase their near-term cash needs, while rebate claims could add paperwork and uncertainty about when funds return. For safety-net and rural providers with limited financial flexibility, those effects could influence budgets for services supported by 340B savings.

The AHA says hospitals use those savings to maintain services, expand access to medicines and support areas such as behavioral health and oncology care. Those are the association’s descriptions of how the program supports care; the lawsuit’s claims about costs have not yet been resolved by the court. If the policy begins as scheduled, its practical effect will depend on the rebate process and how quickly eligible claims are paid.

There is also a wider policy disagreement. Drug companies say some hospitals benefit financially without sufficient accountability, while hospital groups contend that the program helps them serve patients and that a rebate model could weaken that support. The court case will test whether the administration can implement the proposed change and whether the groups’ legal challenge succeeds.

Earlier Court Fight Over 340B

The current dispute follows an earlier administration effort to introduce a similar rebate approach. According to the report, courts blocked that prior effort. Maureen Testoni, president and CEO of 340B Health, which represents more than 1,600 program participants, called the new proposal a rerun of that approach and said the earlier plan was blocked after courts found it likely violated federal administrative law. That characterization is Testoni’s account of the prior litigation and the current proposal.

340B has also faced criticism from drug manufacturers over its scale and oversight. PhRMA says hospitals can buy medicines at steep discounts and sell them at much higher prices, and argues there are too few safeguards governing use of the resulting funds. Hospital advocates dispute the implication that growth in spending proves overuse, pointing to changes such as more care being delivered in outpatient settings and increased use of expensive specialty drugs. The competing explanations have not been settled by the figures cited in the report.

“The proposed shift from upfront 340B discounts to a rebate-based system would place significant financial pressure and administrative burdens on hospitals and clinics that rely on 340B savings to support essential patient care services.”

— Guy Hudson, president and CEO of Northern Light Health

Court Ruling and Cost Questions

The court has not yet ruled on the hospitals’ request, and the case’s outcome remains undecided. The report says briefing is expected to conclude in mid-November, after which the judge will decide whether oral arguments are needed. A decision is expected before the scheduled January 1 start, but the timing and result are not guaranteed.

The source material does not provide a final assessment of the rebate system’s actual costs, the precise mechanics for processing claims, or how quickly hospitals would receive payments. The estimate of more than $1 billion in annual administrative costs comes from the AHA, while PhRMA’s claims about hospital profits and oversight are the trade group’s position. The court filing and available figures do not settle those broader disputes.

Briefing Before the January Start

The parties are due to complete court briefing in mid-November 2026. The judge will then determine whether oral arguments are necessary and consider the hospitals’ request to cancel the planned change. The next major milestone is a ruling before the policy’s scheduled January 1, 2027 start, as anticipated in the report.

Until the court acts, the administration’s proposed timeline remains in place, but the lawsuit could affect whether the rebate model proceeds as scheduled. Hospitals, drug manufacturers and patients served by participating organizations will be watching for the ruling and for further details about implementation. No final outcome has been announced.

Key Questions

What change are hospitals challenging?

The proposal would replace upfront 340B discounts with a system in which hospitals pay regular prices for covered medicines and seek rebates after dispensing them.

Who filed the lawsuit?

The plaintiffs include the American Hospital Association, four safety-net hospitals and the Maine Hospital Association. They are asking the court to cancel the change and restore the current approach.

When could the rebate system begin?

The change is scheduled to take effect on January 1, 2027. A court decision is expected before that date, but the ruling and its timing are not certain.

How much could the change cost hospitals?

The AHA says estimates indicate the system could add more than $1 billion in annual administrative costs. That is the association’s estimate, not a final court finding or confirmed cost.

Why do drug manufacturers oppose aspects of 340B?

PhRMA argues that the program has expanded and that hospitals do not face adequate safeguards for how they use savings. Hospital groups dispute the manufacturers’ criticism and say 340B resources support care for underserved communities.

Source: rss